1
|
Gauthier C, Mariot J, Daurat M, Dhommee C, El Cheikh K, Morère E, Depaepe G, Gary-Bobo M, Morère A, Garcia M, Basile I, Gouilleux-Gruart V, Maynadier M. Mannose 6-phosphate receptor-targeting antibodies preserve Fc receptor-mediated recycling. J Control Release 2023; 358:465-475. [PMID: 37169177 DOI: 10.1016/j.jconrel.2023.05.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 04/21/2023] [Accepted: 05/08/2023] [Indexed: 05/13/2023]
Abstract
The concept of grafting mannose 6-phosphonate derivatives (M6Pn), named AMFA, on therapeutic proteins was first developed for the improvement of enzyme delivery in lysosomal storage disorders. This glycoengineering increases the cellular uptake of the protein via the cation-independent mannose 6-phosphate receptor (M6PR) which further allows their targeting to the lysosomes. In the present study, we investigated the extent to which the direct grafting of AMFA onto a drug, here monoclonal antibody (mAb), affects the cell uptake and recycling of the antibody. The antibodies infliximab (IFX) and adalimumab (ADA), directed against the tumor necrosis factor α (TNFα), grafted with AMFA acquired an affinity for the M6PR, resulting in a >3-fold increase in drug release in cells. Subsequently, the impact of AMFA grafting to the Fc portion of mAb on its affinity for the neonatal Fc receptor (FcRn), which is the key receptor for antibody recycling, was evaluated. Whether one to three AMFA moieties were grafted, FcRn-mediated recycling of mAb were not affected. AMFA grafting did not impair the pharmacokinetics of both ADA and IFX and presented a high stability since AMFAs were still bound to mAb in the plasma of mice 21 days after the treatment. In conclusion, this type of antibody engineering with a reduced number of AMFA confers M6PR targeting property and increases endocytosis, and yet appears fully compatible with FcRn binding and with antibody recycling and transcytosis.
Collapse
Affiliation(s)
- Corentin Gauthier
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France; IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France
| | - Julie Mariot
- Université de Tours, EA 7501, GICC, 10 boulevard Tonnellé, F-37032 Tours, France
| | - Morgane Daurat
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France
| | - Christine Dhommee
- Université de Tours, EA 7501, GICC, 10 boulevard Tonnellé, F-37032 Tours, France
| | - Khaled El Cheikh
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France
| | - Elodie Morère
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France; IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France
| | - Geoffrey Depaepe
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France; IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France
| | | | - Alain Morère
- IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France
| | - Marcel Garcia
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France
| | - Ilaria Basile
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France
| | - Valérie Gouilleux-Gruart
- Université de Tours, EA 7501, GICC, 10 boulevard Tonnellé, F-37032 Tours, France; CHU de Tours, Laboratoire d'immunologie, F-37032 Tours, France.
| | - Marie Maynadier
- NanoMedSyn, 15 avenue Charles Flahault, 34093 Montpellier, France.
| |
Collapse
|